[Temporary Announcement] Baimeike: Independent opinions of independent directors on matters related to the fourth meeting of the second board of directors
Announcement number: 2025-107
Securities code: 874640 Securities abbreviation: BIMIKE Sponsored securities firm: Great Wall Securities Independent Director of Hainan BIMIKE Medical Technology Co., Ltd.
Independent opinions on matters related to the fourth meeting of the second board of directors
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.
1. Deliberation and voting status
Hainan Baimeike Medical Technology Co., Ltd. (hereinafter referred to as the "Company") held the fourth meeting of the second board of directors on October 30, 2025, and reviewed and approved the "Proposal on Approving the Issuance of the Audit Report for January-June 2025", "The Proposal on Approving the Issuance of the Company's Triennial Non-Recurring Profit and Loss Detailed Statement and Special Audit Report" and "The Proposal on Approving the Issuance of the Company's Internal Control Self-Evaluation Report and Audit Report". As the company's independent directors, after carefully reviewing the relevant meeting materials and based on our own independent judgment, we reviewed the relevant proposals submitted for consideration at the fourth meeting of the company's second board of directors, and now express our independent opinions on matters related to the fourth meeting of the company's second board of directors.
2. Independent opinions of independent directors on relevant matters
(1) Independent opinion on the “Proposal on Approving the Issuance of the Audit Report from January to June 2025”
After review, we believe that the preparation of the financial statements and audit reports from January to June 2025 complies with relevant laws and regulations, truly, objectively and accurately reflects the company's financial status, operating results and cash flow situation from January to June 2025. There are no false records, misleading statements or major omissions, and there are no circumstances that damage the interests of the company, all shareholders, especially small and medium-sized shareholders.
In summary, we unanimously agree with the "Proposal on Approving the Audit Report for January-June 2025".
(2) Independent opinion on the "Proposal on Approving the Submission of the Company's Three-Year Non-recurring Profit and Loss Detailed Statement and Special Audit Report"
Announcement number: 2025-107
After review, we believe that: the company's non-recurring profit and loss details and special audit reports for 2022, 2023, 2024, and January-June 2025 are in compliance with relevant laws and regulations, and truly, objectively and accurately reflect the company's 2022, 2023, 2024, and 2025 1-6 The monthly non-recurring profits and losses did not harm the interests of the company or all shareholders, especially small and medium-sized shareholders.
In summary, we unanimously agree with the "Proposal on Approving the Submission of the Company's Three-year Non-recurring Profit and Loss Detailed Statement and Special Audit Report".
(3) Independent opinion on the “Proposal on Approving the Submission of the Company’s Internal Control Self-Evaluation Report and Audit Report”
After review, we believe that: the preparation of the company's internal control self-evaluation report and audit report complies with relevant laws and regulations, and truly, objectively and accurately reflects the construction and implementation of the company's internal control system; the company's internal control system is standardized, reasonable, effective and can be implemented, and does not contain major flaws or damage the interests of the company and all shareholders, especially small and medium-sized shareholders.
In summary, we unanimously agree with the "Proposal on Approving the Issuance of the Company's Internal Control Self-Evaluation Report and Audit Report".
Independent directors of Hainan Baimeike Medical Technology Co., Ltd.: Wang Chaoxin and Sun Qi
October 30, 2025